Sanofi (NASDAQ:SNY) is reporting third quarter earnings results on Thursday 29th October 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 1.09 per share.
For the full year, analysts predict revenues of $ 43207.50 million, while looking forward to income of $ 3.44 per share.
The Company Outlook
Full Year 2020 bottomline are predicted in a range of $ 6.73 ~ $ 6.86 per share
Click Here For More Historical Outlooks Of Sanofi
Previous Quarter Performance
Sanofi unfold income for the second quarter of $ 1.41 per share, from the revenue of $ 9,038.00 million. Street analysts expected $ 9890.00 million. The top line results fell short of analysts by $ 852 million or 8.61 percent.
Stock Performance
Shares of Sanofi traded low $ -1.26 or -2.66 percent on Wednesday, reaching $ 46.14 with volume of 2.18 million shares. Sanofi has traded high as $ 46.79 and has cracked $ 46.04 on the downward trend
According to the previous trading day, closing price of $ 46.14, representing a 26.00 % increase from the 52 week low of $ 37.62 and a 13.82 % decrease over the 52 week high of $ 55.00.
The company has a market capital of $ 116.98 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia in adults and children; and Cablivi to treat acquired thrombotic thrombocytopenic purpura in adults.
